Nukui M, Nakao M, Nakagawa S, Toyoda K, Takada H, Ebisui K, Watanabe H, Miyakoda K, Kobayashi T, Fujiwara M
Department of Urology, Kyoto Prefectural University of Medicine.
Hinyokika Kiyo. 1989 Mar;35(3):415-20.
Nineteen patients with hormonal refractory adenocarcinoma of the prostate were treated with ifosfamide (IFM) and the combination of vincristine, ifosfamide and peplomycin (VIP). Nine of them were treated with IFM, and nine with VIP, and one with IFM and also VIP. In the case of the IFM therapy, the over-all response rate was 0% by the Karnofsky's category of response, 20% by the response criteria of Shida et al., 50% by the National Prostatic Cancer Project (NPCP) criteria, and 0% by the response criteria of Koyama and Saito. In the case of the VIP therapy, the over-all response rate was 30% by the Karnofsky's category, 30% by the response criteria of Shida et al., 70% by the NPCP criteria and 20% by the response criteria of Koyama and Saitoh. The one-year survival rates of these patients treated with IFM and VIP were both about 20%. Only one patient treated with VIP therapy showed a partial response. Therefore, a more effective regimen for hormonal refractory adenocarcinoma of the prostate must be developed.
19例激素难治性前列腺腺癌患者接受了异环磷酰胺（IFM）以及长春新碱、异环磷酰胺和培洛霉素联合方案（VIP）治疗。其中9例接受IFM治疗，9例接受VIP治疗，1例同时接受了IFM和VIP治疗。在IFM治疗组中，根据卡诺夫斯基反应分类法总体缓解率为0%，根据志田等人的反应标准为20%，根据国家前列腺癌项目（NPCP）标准为50%，根据小山和斋藤的反应标准为0%。在VIP治疗组中，根据卡诺夫斯基分类法总体缓解率为30%，根据志田等人的反应标准为30%，根据NPCP标准为70%，根据小山和斋藤的反应标准为20%。接受IFM和VIP治疗的这些患者的一年生存率均约为20%。仅1例接受VIP治疗的患者出现部分缓解。因此，必须开发出一种更有效的激素难治性前列腺腺癌治疗方案。
